Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Redcare Pharmacy Aktie 34117753 / NL0012044747

10.11.2025 18:32:23

EQS-News: Change in Redcare Pharmacy´s Managing Board: new CFO Hendrik Krampe. 

EQS-News: Redcare Pharmacy N.V. / Key word(s): Personnel
Change in Redcare Pharmacy´s Managing Board: new CFO Hendrik Krampe. 

10.11.2025 / 18:32 CET/CEST
The issuer is solely responsible for the content of this announcement.


Change in Redcare Pharmacy´s Managing Board:
new CFO Hendrik Krampe. 

Sevenum, the Netherlands, 10 November 2025. Redcare Pharmacy’s Supervisory Board has designated Hendrik Krampe as member of the Managing Board and Chief Financial Officer, effective 1 December 2025. He succeeds Jasper Eenhorst, who stepped down to pursue new professional opportunities. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation.

Björn Söder, Chairman of the Supervisory Board, welcomes the planned appointment, saying: “With Hendrik, we are gaining an internationally experienced finance leader with a deep understanding of digital business models. His perspective from two of the world’s most successful online stores will help us build on our strong financial foundation and drive the next phase of profitable growth. We are delighted to welcome him to the Managing Board of Redcare Pharmacy.”

Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business.

His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong Q3 results. It will support the company's aim to increasingly capture economies of scale and improve profitability.

Hendrik Krampe comments: “I am looking forward to joining Redcare Pharmacy at such an exciting stage of its development. The company has built an excellent foundation for continued growth across all the markets it serves. I am impressed by the clear vision and deep expertise of the leadership team and the loyalty of its customers. The key ingredients for sustainable success are certainly there.”

 

___

 

Investor Relations Contact:

Monica Ambrosi (Associate Director, Investor Relations)

investors@redcare-pharmacy.com 

 

Press Contact:

Sven Schirmer (Director, Corporate Communications)

press@redcare-pharmacy.com 

 

About Redcare Pharmacy

Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Pilsen, Settala (Milan), Lille and Eindhoven.

As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13.5 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands.

Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.



10.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Redcare Pharmacy N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: investors@redcare-pharmacy.com
Internet: www.redcare-pharmacy.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y072
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2227246

 
End of News EQS News Service

2227246  10.11.2025 CET/CEST

Analysen zu Redcare Pharmacy (ex Shop Apotheke)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
30.10.25 Redcare Pharmacy Buy Deutsche Bank AG
29.10.25 Redcare Pharmacy Buy Baader Bank
29.10.25 Redcare Pharmacy Sell UBS AG
29.10.25 Redcare Pharmacy Buy Jefferies & Company Inc.
23.10.25 Redcare Pharmacy Buy Deutsche Bank AG
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’465.39 10.11.2025 17:30:00
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com